precision medicine News
-
Metabolism Based Diagnosis and Precision Medicine for Autism Spectrum Disorders
Video of presentation at The National TACA Autism Conference – East Coast in Atlanta, Georgia, March 2019. In this video, Beth Donley shares her history as an autism mom as well as details about the NeuroPointDX NPDX ASD test, which is a blood test that can identify about 30% of children with autism spectrum disorder with an increased risk of an ASD diagnosis. This means that 3 in 19 kids ...
By NeuroPointDX
-
Stem Pharm has been Awarded a $1.5M Phase II NIH SBIR Grant from NINDS
Stem Pharm has been awarded a Phase II NIH SBIR grant (R44NS102088; PI: Dr. Lebakken) through the National Institute Of Neurological Disorders And Stroke (NINDS) entitled: Synthetic hydrogels for biomanufacturing of iPSC-derived neural cells for precision medicine. This effort will use Stem Pharm’s hydrogel coatings for efficient differentiation and maturation of iPSC-derived neurons that ...
-
Dr. Warren Flood steps up as CEO of Bio-Me
Microbiome precision medicine company Bio-Me today announced that Dr. Warren Flood has become CEO following his successful period as COO. Previous CEO Dr. Morten Isaksen moves up to the Board and will also continue as Chief Innovation Officer with a focus on longer term and higher-value clinical applications for the company’s Precision Microbiome Profiling (PMP™) technology. These ...
By Bio-Me
-
Thermo Fisher Scientific Sponsors Precision Medicine Summit in China
Thermo Fisher Scientific, the world leader in serving science, today sponsored the first China-U.S. Precision Medicine Summit, along with co-hosts CEO Roundtable on Cancer, China Academy of Medical Sciences and Peking Union Medical College. The Summit convened more than 400 leaders from across government, academia and industry to promote partnership and collaboration that will lead to advances in ...
-
A new study confirming correlation between Biomechanical Markers and clinical outcomes in knee OA patients
A new study published in BMC Musculoskeletal Disorders confirmed that biomechanical markers are more associated with pain, symptoms and disability compared to imaging findings in knee osteoarthritis patients. Researchers recommend the use of a complementary objective biomechanical evaluation using the KneeKG to conventional imaging to obtain a more complete functional profile of knee OA ...
By Emovi
-
Our co-founders and SAB scientific publications among the Top 100 in Cell and Molecular Biology
Last week, the Nature Group Scientific Reports journal published the top 100 most downloaded cell and molecular biology papers. This comprehensive list featured an outstanding publication from our co-founders and SAB members on Precision modification of the human gut microbiota based on selective targeting of surface-associated proteins.Importantly, it is one of the few manuscripts ...
-
SEngine Precision Medicine to Present Pan Cancer Data on Predictive Value of PARIS Test at 2021 ASCO Annual Meeting
SEATTLE, April 29, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on live tumor specimens employing its CLIA certified PARIS® Test, today announced that new data from a study summarizing the predictive value of the PARIS® Test across solid tumor cancers will be presented during a poster session (abstract number 2602) at the American ...
-
SEngine Precision Medicine Announces New Collaboration to Bring PARIS Test to Patients with CNS Cancers
SEATTLE, Nov. 10, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine and Dana-Farber Cancer Institute today announced a collaboration to bring SEngine’s PARIS® Test to adult and pediatric patients with primary or metastatic solid-tumor central nervous system (CNS) cancers. The collaboration aims to provide patients and their oncologists with more information as to what therapies could ...
-
SEngine Precision Medicine Announces New Non-Small Cell Lung Cancer Study at Johns Hopkins University
SEATTLE, Sept. 27, 2022 (GLOBE NEWSWIRE) -- SEngine Precision Medicine Inc., a Seattle-based precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived 3D cultures, is conducting a Non-Small Cell Lung Cancer (NSCLC) study at the esteemed Johns Hopkins University. Lung cancer is the leading cause of cancer death accounting for almost one quarter of annual ...
-
SEngine Precision Medicine Partners with Vincere Cancer Center to Increase Access for First Responders to Get Personalized Cancer Treatments via the PARIS Test
SEATTLE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Seattle-based Precision Oncology company SEngine Precision Medicine and Vincere Cancer Center in Scottsdale, Arizona are collaborating to provide more cancer patients with access to SEngine’s signature diagnostic test, the PARIS® Test. This collaboration, facilitated by Aspire Financial, LLC., will provide SEngine’s cutting-edge ...
-
SEngine Precision Medicine Presents Data at 2021 AACR Annual Meeting Demonstrating Clinical Utility and Predictive Value of PARIS Test in Ovarian Cancer
SEATTLE, April 13, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company that pre-tests drugs on patient-derived live tumor specimens employing its CLIA certified PARIS® Test, today presented results from an ovarian cancer study indicating strong predictive value of the PARIS® Test (abstract number 534) at the American Association for Cancer Research annual ...
-
SEngine Precision Medicine Presents Data Summarizing Predictive Value of PARIS Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium
SEATTLE, Dec. 09, 2020 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived tumor organoids, today presented data from a study summarizing the predictive value of the PARIS® Test in breast cancer tumors as a poster session (PS04/01) at the 2020 San Antonio Breast Cancer Symposium, taking place ...
-
PARIS Test Identified Effective Therapy for Patient with Terminal Ovarian Cancer
SEATTLE, Sept. 13, 2021 (GLOBE NEWSWIRE) -- SEngine Precision Medicine announces dramatic results for a 52-year-old patient with terminal ovarian cancer who received the PARIS® Test in early summer 2020. An interim case summary was included in SEngine’s poster presentation at the AACR 2021 annual meeting. The patient’s oncologist, Heidi Gray, MD, who specializes in ovarian cancer ...
-
SEngine Precision Medicine closes Series A bringing total financing to $19M enabling continued advancement of personalized cancer treatments
SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Seattle-based Precision Oncology company SEngine Precision Medicine has now raised a total of $19M, following the recent closing of a $10M Series A2, as it continues to commercialize a platform that matches cancer patients to the right drug and also drives drug discovery. The Series A2 round was led by the Washington Research Foundation along with ...
-
Population Diagnostics Announces Corporate Name Change to Population Bio to Signify its Broad Precision Medicine Focus
Melville, NY, (December 21, 2016) Population Diagnostics – a global leader in gene discovery for complex disease announced today that it is changing its corporate name to Population Bio. The name change reflects the company's broader commitment to precision medicine and its expertise in driving the innovations needed to shape the future of drug development and predictive diagnostics. The ...
-
Getting Personal with Precision Medicine – PharmaVOICE
Research on biologics, the study of the human genome, and the development of precision diagnostic tools and software have led to new hopes for the development of promising precision medicine. At the same time, the life-sciences commercial sector is still struggling with the challenges of payment structures and value assessment frameworks. As originally conceived, personalized medicine referred ...
By NeuroPointDX
-
The transformation of precision medicine in infectious disease
Before Alexander Fleming discovered penicillin, another more selective antibacterial agent rose to popularity in the early 1900s: bacteriophage. In 1917, microbiologist Felix d’Herelle was tasked with identifying the cause of a dysentery outbreak impacting French troops. From his research, he noticed that Shigella bacteria was the primary culprit of this affliction. He then discovered an ...
-
Improving Medicine with Philosophy of Science
Philosophy addresses issues that can’t be settled by facts alone, and the philosophy of science is the application of this approach to the domain of science [1]. More than ever we need philosophical analysis and perspective to realize the benefits of science, particularly in the realm of health and healing. We recently attended the Philosophy of Science Association’s 26th biennial ...
By Echobio, LLC
-
STALICLA strengthens pipeline to advance precision medicine for Autism Spectrum Disorders
STALICLA SA, a precision neuroscience clinical stage biotech advancing the first precision medicine platform for patients with Neurodevelopmental Disorders, has in-licensed SFX-01 from Evgen Pharma plc in neurodevelopmental disorders and schizophrenia. The first indication targets a biologically characterised subgroup of patients with Autism Spectrum Disorder (ASD) STALICLA's unique approach ...
By STALICLA
-
SeqOne Genomics selected as genomic analysis solution for CELIA (Comprehensive Genomic profiling impact) project, in collaboration with Illumina
The project aims to compare the clinical utility of broad-spectrum genomic profiling in the treatment of late-stage cancer patients with more traditional approaches that analyze a limited set of genes and thus influence the precision medicine strategy of the French national health system SeqOne Genomics, developer of next generation genomic analysis solutions, announced that it has been selected ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you